HnRNPK-targeted lentivirus shRNA and application thereof

Through the lentiviral shRNA targeting hnRNPK interferes with hnRNPK gene expression, the problem of poor sensitivity of esophageal cancer to radiotherapy is solved, significantly reduces the invasion of esophageal cancer cells and wound healing ability, enhances the sensitivity of esophageal cancer cells to radiation, and provides new treatment strategies.

CN118956873AInactive Publication Date: 2024-11-15NANTONG TUMOR HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411184222.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Patients with esophageal cancer have poor sensitivity to radiotherapy, resulting in uneven radiotherapy effects and high recurrence rates, and lack of effective strategies to enhance radiosensitivity of esophageal cancer.

Method used

A lentiviral shRNA targeting hnRNPK was designed to reduce the proliferation, invasion and wound healing ability of esophageal cancer cells by interfering with hnRNPK gene expression and enhance the sensitivity of esophageal cancer cells to radiation.

Benefits of technology

Through the lentiviral shRNA targeting hnRNPK, it significantly reduces the invasion of esophageal cancer cells and wound healing ability, enhances the sensitivity of esophageal cancer cells to radiation, provides a new gene target and drug, and has high clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956873A_ABST
    Figure CN118956873A_ABST
Patent Text Reader

Abstract

The invention discloses an hnRNPK-targeted lentivirus shRNA (short hairpin Ribonucleic Acid) and application thereof, and belongs to the technical field of molecular biotechnology and genetic engineering. The invention discloses a lentivirus shRNA (short hairpin ribonucleic acid) targeted by hnRNPK (human nRNPK). The sequence of the lentivirus shRNA is shown as SEQ ID NO. 1 and SEQ ID NO. 2. After esophageal cancer cells ECA109 and KYSE150 are transfected by the lentivirus shRNA, hnRNPK gene expression can be effectively regulated and interfered, so that proliferation and clone formation capabilities of the esophageal cancer cells are reduced, and wound healing and invasion of the esophageal cancer cells are inhibited; therefore, the lentivirus shRNA targeted by the hnRNPK gene has the functions of reducing the expression of the hnRNPK, effectively inhibiting the proliferation, migration and invasion of esophageal cancer cells and enhancing the radiosensitivity of the esophageal cancer, provides a new gene target and medicine for the radiosensitivity of the esophageal cancer, and has very high clinical practical application value.
Need to check novelty before this filing date? Find Prior Art